IMNM Valuation

Immunome Inc

Add to Watchlist

Advanced Chart

8.850

-0.010(-0.110%)

Overview
Forecast
Valuation

IMNM Relative Valuation

IMNM's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, IMNM is overvalued; if below, it's undervalued.

Historical Valuation

Immunome Inc (IMNM) is now in the Overvalued zone, suggesting that its current forward PS ratio of 393.68 is considered Overvalued compared with the five-year average of 58.66. The fair price of Immunome Inc (IMNM) is between 2.70 to 5.83 according to relative valuation methord. Compared to the current price of 8.85 USD , Immunome Inc is Overvalued By 51.84%.

Relative Value

Fair Zone

2.70-5.83

Current Price：8.85

51.84%

Overvalued

Trailing

Forward

P/E

EV/EBITDA

EV/EBIT

P/S

P/OCF

P/FCF

Trailing

Forward

3.15

P/B

Median3y

5.05

Median5y

4.50

-21.50

FCF Yield

Median3y

-20.42

Median5y

-17.27

Competitors Valuation Multiple

The average P/S ratio for IMNM's competitors is 115.38, providing a benchmark for relative valuation. Immunome Inc Corp (IMNM) exhibits a P/S ratio of 393.68, which is 241.19% above the industry average. Given its robust revenue growth of -28.44%, this premium appears unsustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

P/S

Revenue Growth

Market Cap